"Lymph node biopsy"

Sentinel Lymph Node Biopsy for intermediate thickness melanoma 1 Public Summary Document Application No. 1485.1 – Sentinel Lymph Node Biopsy for intermediate thickness melanoma Applicant: The Australian Society of Specialist General Surgeons Date of MSAC consideration: MSAC 78th Meeting, 3 April 2020 Context for decision: MSAC makes its advice in accordance with its Terms of Reference , visit the MSAC website 1. Purpose of application A resubmission requesting Medicare Benefits Schedule (MBS) listing for sentinel lymph node biopsy (SLNBx) in patients with primary melanomas ≥1.0 mm Breslow thickness, or those ≥0.8 mm with high-risk features (e.g. ulceration), was received from the Australian Society of Specialist General Surgeons by the Department of Health. 2. MSAC’s advice

Are Clinically Node-Negative Patients with a Positive Preoperative Axillary Lymph Node Biopsy Appropriate Candidates for Sentinel Lymph Node Biopsy?

A multicenter noninferior randomized controlled study of sentinel lymph node biopsy alone versus sentinel lymph node biopsy plus lymphadenectomy for patients with stage I endometrial cancer, INSEC trial concept. Up to the present time, there has remained a lack of strong evidence as to whether sentinel lymph node biopsy can replace lymphadenectomy for early endometrial cancer. The traditional mortality. The current trial is designed to clarify whether sentinel lymph node biopsy can replace lymphadenectomy for early endometrial cancer patients with negative lymph nodes. This study is a randomized, open-label, multicenter and non-inferiority controlled clinical trial in China. Potential participants will be patients with pathologically confirmed endometrial cancer at the Zhejiang Cancer Hospital

Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH Skip to main content * About * Collaboration/Outreach * Patient/Community * Careers * Contact * My CADTH * FR * My CADTH Breadcrumb 1. Home 2. Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Copied to clipboard Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines ( Last Updated : March 2, 2020) Project Line: Health Technology Review Project Sub

Comparison of Indocyanine Green with conventional tracers for sentinel lymph node biopsy in breast cancer: A multidisciplinary evaluation of clinical effectiveness, safety, organizational and economic impact. Breast cancer is a global health problem, and sentinel lymph node biopsy (SLNB) is the standard procedure for early-stage breast cancer. Technetium-99 (TC-99), alone or combined with blue

The Effectiveness of Superparamagnetic Iron Oxide Nanoparticles in Reducing Unnecessary Sentinel Lymph Node Biopsies. Sentinel lymph node biopsy (SLNB) is routinely performed at the time of mastectomy for noninvasive breast disease owing to the potential upgrade on final pathology, resulting in 80% of patients receiving unnecessary SLNB. Superparamagnetic iron oxide nanoparticles (SPIO

Comparison of Technetium-99m Tilmanocept to Technetium-99 Sulfur Colloid Radiotracer for Sentinel Lymph Node Biopsy in Head and Neck Melanoma. Sentinel lymph node biopsy (SLNB) is integral to management of head and neck melanomas (HNM). Here, we evaluate how radiotracer selection (Tc-99m tilmanocept or Tc-99m sulfur colloid) and imaging modality (planar imaging or single positron emission

How to Perform Bilateral Sentinel Lymph Node Biopsy in Vulvar Cancer with Indocyanine Green by Video-Endoscopic Approach. The standard surgical treatment of early stage vulvar carcinoma < 4 cm consists of resection of the vulvar tumor with sentinel lymph node (SLN) biopsy (Oonk in Int J Gynecol Cancer 33:1023-1043, 2023). Video-endoscopic inguinal SLN biopsy with indocyanine green (ICG) has been

Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis. Standard management of early-stage cervical cancer is hysterectomy with bilateral pelvic lymph node evaluation. Based on the final results of the prospective international SENTIX Trial, we sought to determine the cost-effectiveness (CE) of type of lymph node assessment for early

Predictors of Sentinel Lymph Node Biopsy in Thin Melanoma: Understanding the Impact of the American Joint Commission on Cancer 8th Edition Staging System. The definition of T1b cutaneous melanoma was changed in the 8th edition of the AJCC staging system based on survival differences but not risk of sentinel lymph node (SLN) metastases. We sought to evaluate changes in SLN biopsy (SLNB) use

Better-Defined Morbidity of Sentinel Lymph Node Biopsy in Patients with Melanoma. Sentinel lymph node biopsy (SLNB) is crucial for staging malignant melanoma, but introduces additional risks and costs. This study aims to evaluate the quality and morbidity of SLNB at our institution. We conducted a retrospective analysis of patients who underwent SLNB between 2017 and 2024. Patients were included

An Evaluation of Sentinel Lymph Node Biopsy Guideline Adherence in Melanoma. Regional lymph nodes are a common first site of metastasis in patients diagnosed with invasive melanoma. Knowledge of sentinel lymph node status provides strong prognostic information in melanoma and is important for staging and treatment decisions. The National Comprehensive Cancer Network (NCCN) recommends performance of sentinel lymph node biopsy (SLNB) for melanoma patients with a T category of ≥T2a. This study aims to assess our academic institution's guideline adherence to improve quality of care. Retrospective review of medical records from 2017 to 2023 identified 628 patients referred to our institution for invasive melanoma treatment. Adherence to guidelines was assessed using Chi-square analyses and Fisher's

Sentinel lymph node biopsy in gynecological malignancies: A modern approach to surgical staging - A narrative review. Sentinel lymph node biopsy (SLNB) has emerged as a valuable alternative to traditional lymphadenectomy in the surgical management of gynecological cancers. This narrative review delves into the advantages, practical applications, and future research directions of SLNB

Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study. Sentinel lymph node biopsy (SLNB) aims to stage patients. According to the 8th edition of the American Joint Committee on Cancer(AJCC) staging manual, patients with pT1b or pT2a melanoma can be eligible for adjuvant immunotherapy, however, only if they have a sentinel node

Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins. Our study aims to audit and evaluate the accuracy and pitfalls of intraoperative evaluation of frozen sentinel lymph nodes (IOE-FSLN) and resection margins (IOE-FSM) compared to final findings in paraffin sections. A total of 264 cases underwent

Evaluation of the efficacy of using indocyanine green associated with fluorescence in sentinel lymph node biopsy. Sentinel lymph node biopsy is the technique recommended for the axillary staging of patients with breast cancer in the initial stages without clinical axillary involvement. Three techniques are widely used globally to detect sentinel lymph nodes: patent blue, the radiopharmaceutical

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes

Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. The introduction of adjuvant systemic treatment for patients with high-risk melanomas necessitates accurate staging of disease. However, inconsistencies in outcomes exist between disease stages as defined by the American Joint Committee on Cancer (8th edition). We aimed to develop a tool to predict patient-specific outcomes in people with melanoma rather than grouping patients according to disease stage. Patients older than 13 years with confirmed primary melanoma who underwent sentinel lymph node biopsy (SLNB) between Oct 29, 1997, and Nov 11, 2013, at four European

De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. Melanoma disease patterns vary with patient age. To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages. Online prediction tools were applied to compare SLNB positivity (SLNB ) and survival risk at patient ages 20-80. Tübingen melanoma data were